Amifostine in the management of radiation-induced and chemo-induced mucositis

[1] Antonadou D(2002)Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer Semin Radiat Oncol 12 50-58

[2] Antonadou D(2002)Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer Int J Radiat Oncol Biol Phys 52 739-747

[3] Pepelassi M(2003)Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 57 402-408

[4] Synodinou M(2002)Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation Semin Radiat Oncol 12 59-61

[5] Puglisi M(2003)Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial Int J Radiat Oncol Biol Phys 56 1154-1160

[6] Throuvalas N(2002)Preliminary data of the GORTEC 2000–02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy Semin Oncol 29 57-60

[7] Antonadou D(2003)Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study Bone Marrow Transplant 32 1071-1075

[8] Throuvalas N(2002)A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury Int J Radiat Oncol Biol Phys 53 1160-1164

[9] Petridis A(2002)Intrarectal application of amifostine for the prevention of radiation-induced rectal injury Semin Radiat Oncol 12 81-85

[10] Bolanos N(2002)New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion J Clin Pharmacol 42 166-174

[1] Antonadou D(2002)Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer Semin Radiat Oncol 12 50-58

[2] Antonadou D(2002)Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer Int J Radiat Oncol Biol Phys 52 739-747

[3] Pepelassi M(2003)Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 57 402-408

[4] Synodinou M(2002)Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation Semin Radiat Oncol 12 59-61

[5] Puglisi M(2003)Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial Int J Radiat Oncol Biol Phys 56 1154-1160

[6] Throuvalas N(2002)Preliminary data of the GORTEC 2000–02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy Semin Oncol 29 57-60

[7] Antonadou D(2003)Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study Bone Marrow Transplant 32 1071-1075

[8] Throuvalas N(2002)A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury Int J Radiat Oncol Biol Phys 53 1160-1164

[9] Petridis A(2002)Intrarectal application of amifostine for the prevention of radiation-induced rectal injury Semin Radiat Oncol 12 81-85

[10] Bolanos N(2002)New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion J Clin Pharmacol 42 166-174